文献速递膀胱癌与上尿路尿路上皮癌

上尿路尿路上皮癌输尿管镜治疗后的内镜随访:更长随访更优——基于10年数据的评估

Longer is Better for Endoscopic Follow-up of Upper Tract Urothelial Carcinoma After Ureteroscopic Treatment: An Evaluation Spanning 10 Years of Data.
PubMed 文献 · Eur Urol Oncol · 2023-12-05

单中心队列纳入2010年1月至2020年12月接受输尿管镜(URS)治疗的非转移性上尿路尿路上皮癌(UTUC)成人患者71例,中位随访49.5个月。2年无复发生存(RFS)率为22%,低级别病变1年RFS率50%、2年RFS率29%;23例转为根治性肾输尿管切除术(中位时间9.9个月),13例出现肿瘤升级(中位时间21.9个月)。作者认为应将内镜随访延长至现行指南推荐的6个月之后。

要点

  • UTUC经URS治疗后2年RFS率仅22%,低级别病变2年RFS率29%。
  • 23例转为根治性肾输尿管切除术,中位转化时间9.9个月。
  • 13例出现肿瘤升级,中位升级时间21.9个月,多超出指南6个月随访窗。

核心结论

  • 作者认为将URS治疗的UTUC内镜随访延长至现行指南推荐的6个月之后是合理的,因为治疗转化和肿瘤升级等临床相关事件发生于6个月之后。
  • 二次URS结果对随访期间的肿瘤复发或治疗转化无预后价值。

研究设计与样本

  • 单中心队列研究,纳入2010年1月至2020年12月接受URS治疗的非转移性UTUC成人患者71例,中位随访49.5个月。
  • 随访方案为第1年每3个月一次内镜,第2至3年每6个月一次,此后每年一次。
  • 采用Andersen-Gill模型分析肿瘤复发,多变量Cox回归分析低级别肿瘤治疗转化的预测因素。

主要发现

  • 总体2年RFS率为22%;低级别病变1年RFS率50%、2年RFS率29%。
  • 23例转为根治性肾输尿管切除术,中位转化时间9.9个月。
  • 13例出现肿瘤升级,中位升级时间21.9个月。
  • 未发现肿瘤复发或治疗转化的预后因素。
  • 5年总生存(OS)率82%、肿瘤特异性生存(CSS)率86%、无转移生存(MFS)率84%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tumour recurrences are frequent among patients with upper tract urothelial carcinoma (UTUC) treated with ureteroscopy (URS). Therefore, guidelines recommend a strict follow-up regimen, but there is little evidence on how to do this. OBJECTIVE: To analyse outcomes during our follow-up regimen and the impact on treatment in terms of ipsilateral UTUC recurrence, treatment conversion, and tumour upgrading, and to evaluate potential prognostic factors, including second-look URS outcomes. A secondary objective was to evaluate survival outcomes. DESIGN, SETTING, AND PARTICIPANTS: The single-centre cohort included all adult patients with nonmetastatic UTUC treated with URS from January 2010 to December 2020. Follow-up involved endoscopy at 3-mo intervals in the first year, then at 6-mo intervals up to year 3, and yearly thereafter. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Descriptive analyses were performed for the follow-up outcomes. The Andersen-Gill model for recurrent event analysis was used to analyse tumour recurrences, and multivariable Cox regression to analyse for predictors for treatment conversion in low-grade tumours. RESULTS AND LIMITATIONS: We analysed 71 patients with median follow-up of 49.5 mo. The overall 2-yr recurrence-free survival (RFS) rate was 22%. In low-grade disease, the 1-yr RFS rate was 50% and the 2-yr RFS rate was 29%. Treatment was converted to radical nephroureterectomy for 23 patients, at a median time to conversion of 9.9 mo. Upgrading was seen in 13 patients, at a median time to upgrading of 21.9 mo. No factors were prognostic for either tumour recurrence or treatment conversion. The 5-yr OS, CSS, and MFS rates were 82%, 86%, and 84%, respectively. CONCLUSIONS: Our data show that it is rational to extend endoscopic follow-up for UTUC treated with URS, as clinically relevant events (treatment conversion and tumour upgrading) occur beyond the current 6-mo guideline recommendation. Second-look URS outcomes were not prognostic for tumour recurrence or treatment conversion during follow-up. PATIENT SUMMARY: Our study results show that for patients with cancer of the upper urinary tract treated with kidney-sparing surgery through a small telescope called a ureteroscope (URS), most of the clinically relevant events (treatment conversion and tumour upgrading) occur outside the current recommended follow-up of 6 months. Therefore, URS follow-up should be extended for these patients.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Figaroa OJA, Hendriks N, Kamphuis GM, et al. Longer is Better for Endoscopic Follow-up of Upper Tract Urothelial Carcinoma After Ureteroscopic Treatment: An Evaluation Spanning 10 Years of Data. Eur Urol Oncol. 2023. PMID: 38057192. doi:10.1016/j.euo.2023.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。